Diacylglycerol kinase α activator
Flavanones from almond seed coats serve as potent DGKα activators, addressing the limited efficacy of existing activators by enhancing DGKα activation to treat diabetic nephropathy.
Patent Information
- Application Number
- JP2020095378
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-06-01
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2040-06-01
AI Technical Summary
There is a need for new ingredients that can effectively activate diacylglycerol kinase α (DGKα) to prevent or improve diabetic nephropathy, as existing activators like vitamin E and gallate-type catechins are limited in efficacy.
Flavanones, particularly those derived from almond seed coat extracts, are used as DGKα activators, enhancing the activation of DGKα to convert diacylglycerol to phosphatidic acid, thereby reducing protein kinase C activity and mitigating diabetic nephropathy.
Flavanones, especially from almond seed coats, effectively activate DGKα, potentially preventing or improving diabetic nephropathy through dietary therapy, offering a novel and sustainable use for waste materials.
Smart Images

Figure 0007594371000005 
Figure 0007594371000006 
Figure 0007594371000007
Abstract
Description
[Technical field]
[0001] The present invention relates to a diacylglycerol kinase α activator that can be used in foods, medicines, etc. and that can effectively activate diacylglycerol kinase α (DGKα). [Background technology]
[0002] Diabetic nephropathy is one of the microvascular complications of diabetes, and is the number one primary renal disease leading to the introduction of hemodialysis. There is no practical treatment for diabetic nephropathy, and the basis of treatment is dietary therapy and control of blood sugar and blood pressure.
[0003] There are various factors that cause the onset and aggravation of diabetic nephropathy, and it has been elucidated that one of the factors is the activation of protein kinase C (PKC) by diacylglycerol (DG) synthesized from blood glucose. Meanwhile, DGKα is a lipid kinase that phosphorylates DG to convert it to phosphatidic acid, and it has been reported that the activation of DGKα indirectly reduces the activity of PKC, which is effective in preventing or improving diabetic nephropathy (see Non-Patent Document 1).
[0004] It has been reported that vitamin E has the effect of activating DGKα (see Non-Patent Document 2). It has also been reported that gallate-type catechins have the effect of activating DGKα, but free catechins do not (Non-Patent Document 3). However, among the ingredients that have been consumed in the past, only vitamin E and gallate-type catechins have been reported to have the effect of activating DGKα.
[0005] Therefore, there is a need to find new components that are effective in the dietary therapy and prevention of diabetic nephropathy. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Isabel Merida et al., Biochem. J., 476, p.1205-1219 (2019). [Non-Patent Document 2] Daiki Hayashi et al., Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome (Second Edition), p.375-383 (2018). [Non-Patent Document 3] Daiki Hayashi et al., J. Functional Foods, 15, p.561-569 (2015). Summary of the Invention [Problem to be solved by the invention]
[0007] An object of the present invention is to provide a DGKα activator that can effectively activate DGKα.
[0008] The present inventors have conducted extensive research to solve the above problems and have found that flavanones have excellent DGKα activation activity and can be used as DGKα activators. The present inventors have also found that almond seed coat extract contains flavanones and has a significantly excellent DGKα activation activity. The present invention was completed based on these findings and further research.
[0009] That is, the present invention provides the following aspects. Item 1. DGKα activators, including flavanones. Item 2. The DGKα activator according to Item 1, wherein the flavanones include at least one selected from the group consisting of flavanone, naringenin, and glycosides thereof. Item 3. The DGKα activator according to Item 1 or 2, wherein the flavanones include a plant extract containing flavanones. Item 4. The DGKα activator according to Item 3, wherein the plant extract is an almond seed coat extract. Item 5. A food or drink for activating DGKα, comprising the DGKα activator according to any one of Items 1 to 4. Item 6. The food or drink for activating DGKα according to Item 5, which is used in dietary therapy for diabetes patients or patients with diabetic nephropathy. Item 7. A pharmaceutical for activating DGKα, comprising the DGKα activator according to any one of items 1 to 4. Effect of the Invention
[0010] According to the DGKα activator of the present invention, DGKα can be activated using flavanones that are commonly consumed, and therefore, diabetic nephropathy can be prevented or improved by taking the DGKα activator of the present invention through dietary therapy, etc. In addition, one embodiment of the present invention uses an almond seed coat extract, which is advantageous in that it makes effective use of almond seed coats that are otherwise considered waste. [Brief description of the drawings]
[0011] [Figure 1] In Test Example 1, a translocation assay of GFP-DGKα was performed, and images of cells observed with a confocal fluorescence microscope are shown. [Diagram 2] FIG. 1 shows the results of performing a GFP-DGKα translocation assay in Test Example 1 to measure the translocation rates of DGKα to the cell membrane for almond seed coat extract, flavanone, naringenin, and epicatechin gallate (positive control), and calculating the ratios (relative translocation ratios, %) of the translocation rates of almond seed coat extract, flavanone, and naringenin to the translocation rate of epicatechin gallate (positive control). [Diagram 3]FIG. 1 shows the results of a GFP-DGKα translocation assay performed in Test Example 2 to measure the translocation rate of DGKα to the cell membrane for various concentrations of almond seed coat extract, flavanone, naringenin, and epicatechin gallate (positive control). [Figure 4] FIG. 13 shows the results of a GFP-DGKα translocation assay performed in Test Example 3 to measure the translocation rate of DGKα to the cell membrane for almond seed coat extract and a flavonoid mixture at various concentrations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The DGKα activator of the present invention is characterized in that it contains a flavanone. The DGKα activator of the present invention will be described in detail below.
[0013] [Flavanones] The DGKα activator of the present invention contains flavanones as an active ingredient that activates DGKα.
[0014] Flavanones are aglycones having a 2-phenylchromanone skeleton and their glycosides. The types of flavanones that can be used in the present invention are not particularly limited, and examples thereof include flavanone (2,3-dihydroflavone), naringenin, hesperetin, liquiritigenin, eriodictyol, homoeriodictyol, sakuranetin, isosakuranetin, pinocembrin, sterubin, and glycosides thereof. Specific examples of glycosides include naringenin glycosides such as narirutin, naringin, and prunin; hesperetin glycosides such as hesperidin, neohesperidin, and hesperetin-7-rhamnoside; liquiritigenin glycosides such as liquiritin; eriodictyol glycosides such as eriocitrin and neoeriocitrin; sakuranetin glycosides such as sakuranin; and isosakuranetin glycosides such as poncirin.
[0015] These flavanones may be used alone or in combination of two or more.
[0016] Among these flavanones, from the viewpoint of activating DGKα more effectively, preferred are flavanone, naringenin, and glycosides thereof, and more preferred are flavanone and glycosides thereof.
[0017] In the present invention, the flavanones may be those obtained from natural products such as plants, or may be those obtained synthetically or semi-synthetically by chemical synthesis, enzymatic synthesis, etc. Furthermore, in the present invention, purified or crudely purified flavanones may be used as the flavanones, or materials containing flavanones may be used.
[0018] A preferred embodiment of the DGKα activator of the present invention is one in which a plant extract containing flavanones is used as the flavanone. Flavanones are known to be contained in plants such as almond seed coats, tea leaves, citrus fruits, tomato fruits, and rice, and the plant extract containing flavanones can be obtained by subjecting these plant materials to an extraction treatment.
[0019] The extraction treatment for obtaining the plant extract may be a solvent extraction treatment generally used for producing plant extracts.
[0020] The plant material to be subjected to the solvent extraction treatment may be in its raw state as is, or may be subjected to pretreatment such as crushing, cutting, steaming, rolling, drying, roasting, blanching, boiling, etc., as necessary.
[0021] The extraction solvent used in the solvent extraction treatment is not particularly limited as long as it can extract flavanones, and examples thereof include water; monohydric lower alcohols having 1 to 4 carbon atoms, such as methanol, ethanol, n-propanol, isopropanol, and n-butanol; polyhydric alcohols, such as propylene glycol and 1,3-butylene glycol; ketones, such as acetone; aliphatic hydrocarbons, such as hexane and pentane; acids, such as acetic acid and hydrochloric acid; and mixtures thereof. Among these extraction solvents, preferred are water, monohydric lower alcohols, and mixtures thereof; more preferred are water, ethanol, and mixtures thereof; and even more preferred are mixtures of water and ethanol. In addition, the extraction solvent may include acids, such as acetic acid and hydrochloric acid;
[0022] When a mixed solvent of water and a monohydric lower alcohol is used as the extraction solvent, the content of the lower alcohol in the mixed solvent is, for example, 10 to 95% by volume, preferably 20 to 90% by volume, more preferably 30 to 80% by volume, and even more preferably 60 to 80% by volume.
[0023] The solvent extraction treatment may be performed by immersing or refluxing the plant raw material in the extraction solvent. After the solvent extraction treatment, solid matter is removed by solid-liquid separation to obtain a plant extract containing flavanones. The obtained extract may be used as a liquid plant extract as it is or after removing a part of the solvent, or may be used as a solid plant extract by removing all of the solvent.
[0024] The obtained plant extract may be subjected to a purification treatment using an adsorption resin, an ion exchange resin, activated carbon, etc. For example, the obtained plant extract may be adsorbed onto an adsorption resin, and then eluted with an aqueous solution containing 10 to 90% by volume (preferably 20 to 80% by volume, more preferably 20 to 60% by volume) of ethanol, and the eluted fraction may be collected to obtain a plant extract in which flavanones are concentrated.
[0025] Among plant extracts containing flavanones, almond seed coat extract has a unique composition containing flavanones such as flavanones, naringenin, and their glycosides, which dramatically improves the effect of activating DGKα, making it particularly suitable for use as an activating component in the DGKα activator of the present invention.
[0026] [Applications / Amount] The DGKα activator of the present invention is used for activating DGKα. By activating DGKα, DG synthesized from blood glucose is efficiently converted to PA, and as a result, activation of PKC, which is involved in the onset and aggravation of diabetic nephropathy, by DG can be suppressed, so that the DGKα activator of the present invention can be used for preventing or improving diabetic nephropathy.
[0027] For example, since diabetic patients who do not suffer from diabetic nephropathy are at risk of developing diabetic nephropathy, the DGKα activator of the present invention can be used to prevent diabetic nephropathy in such diabetic patients.Furthermore, the DGKα activator of the present invention can be used to improve symptoms of diabetic nephropathy and prevent its aggravation in diabetic nephropathy patients.
[0028] The method of application of the DGKα activator of the present invention is not particularly limited, and examples thereof include oral, enteral, intravenous, intraarterial, subcutaneous, intramuscular, etc. Among these application forms, oral application is preferred from the viewpoint of simple and efficient activation of DGKα in vivo.
[0029] The amount of the DGKα activator of the present invention to be applied may be an effective amount for activating DGKα, and may be appropriately set depending on the type and form of the product used, the expected effect, etc. For example, the daily intake or administration amount of flavanones for adults may be set to about 10 to 3000 mg, preferably about 200 to 1400 mg, more preferably about 400 to 1200 mg, and even more preferably about 600 to 1000 mg. When a plant extract containing flavanones is used, the amount of flavanones in the plant extract may be set to satisfy the above range.
[0030] [Products for which it can be used] The dosage form of a product in which the DGKα activator of the present invention is used is not particularly limited and may be any of solid, semi-solid, or liquid, and may be appropriately selected depending on the application method of the DGKα activator, etc.
[0031] The formulation of the product in which the DGKα activator of the present invention is used is not particularly limited, and examples include foods and beverages, pharmaceuticals, and the like.
[0032] When the DGKα activator of the present invention is used in the field of food and beverages, flavanones (DGKα activators) may be prepared into a desired form either directly or in combination with other food materials or additives, and provided as a food or beverage for activating DGKα. The food or beverage for activating DGKα may be used in dietary therapy for diabetic patients without diabetic nephropathy or for patients with diabetic nephropathy.
[0033] Examples of foods and beverages include general foods and beverages, as well as foods with health claims (including foods for specified health uses, foods with nutritional claims, and foods with functional claims), foods for the sick, etc. The forms of these foods and beverages are not particularly limited, but specifically include supplements such as capsules (soft capsules, hard capsules), tablets, granules, powders, and jellies; main dishes such as bread and noodles; side dishes such as cheese, ham, sausages, and seafood products; confectioneries such as gum, chocolate, soft candy, hard candy, biscuits, cookies, crackers, okaki, rice crackers, and puffed snacks; frozen desserts such as ice cream, soft serve ice cream, sherbet, and frozen desserts; soft drinks, milk drinks, lactic acid bacteria drinks, carbonated drinks, fruit juice drinks, vegetable drinks, vegetable and fruit drinks, powdered drinks, jelly drinks, coffee drinks, black tea drinks, green tea drinks, sports drinks, nutritional drinks, energy drinks, non-alcoholic drinks, and alcoholic drinks.
[0034] When the DGKα activator of the present invention is used in a food or drink, the amount of the DGKα activator in the food or drink may be appropriately set within the range that satisfies the above-mentioned application amount depending on the type and form of the food or drink, for example, the amount of flavanones may be set to 0.001 to 95 mass%, preferably 0.005 to 90 mass%, more preferably 0.01 to 85 mass%. When a plant extract containing flavanones is used, the amount of flavanones in the plant extract may be set to satisfy the above-mentioned range.
[0035] Furthermore, when DGKα activators are used in the pharmaceutical field, flavanones (DGKα activators) may be prepared into a desired dosage form alone or in combination with other pharmacological ingredients, pharma- ceutically acceptable bases and additives, and provided as pharmaceuticals for activating DGKα. There are no particular limitations on the form of such pharmaceuticals, but specific examples include oral pharmaceuticals such as tablets, granules, powders, capsules, soft capsules, and syrups; and pharmaceuticals for systemic administration such as injections and infusions. Among these, oral pharmaceuticals are preferred.
[0036] When the DGKα activator of the present invention is used in a pharmaceutical product, the amount of the DGKα activator in the pharmaceutical product may be appropriately set within the range that satisfies the above-mentioned application amount depending on the type and dosage form of the pharmaceutical product, for example, the amount of flavanones may be set to 0.001 to 95% by mass, preferably 0.005 to 90% by mass, more preferably 0.01 to 85% by mass. When a plant extract containing flavanones is used, the amount of flavanones in the plant extract may be set to satisfy the above-mentioned range. EXAMPLES
[0037] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.
[0038] Production Example 1: Production of almond seed coat extract A and composition analysis The parboiled almond seed coat was dried at 60° C. until the moisture content was less than 5% by weight. Next, a 70% by volume aqueous ethanol solution was added in an amount 10 times (by weight) the amount of the dried almond seed coat, and the mixture was refluxed at 80° C. for 1 hour to carry out a solvent extraction process. The liquid after the solvent extraction process was filtered through a filter paper, and the obtained filtrate was dried to obtain an extract (almond seed coat extract A).
[0039] The polyphenol composition of almond seed coat extract A was analyzed by liquid chromatography time-of-flight mass spectrometry. As a result, it was confirmed that almond seed coat extract A contains at least naringenin glycoside, and the naringenin glycoside content per gram was 0.025 mg.
[0040] Production Example 2: Production of almond seed coat extracts B and C The parboiled almond seed coat was dried at 60°C until the moisture content was less than 5% by weight. Next, a 70% by volume aqueous solution of ethanol was added in an amount 10 times (by weight) to the dried almond seed coat, and the mixture was refluxed at 80°C for 1 hour to perform a solvent extraction process. The liquid after the solvent extraction process was centrifuged (17,000 xg, 15 minutes) to remove solids. Next, the obtained extract was loaded onto a column packed with an adsorption resin ("Diaion HP20", Mitsubishi Chemical Corporation), and washed with 10% by volume aqueous ethanol in an amount 5 times the volume of the column, after which 30% or 50% by volume aqueous ethanol was passed through, and the eluted fraction was collected and dried. The fraction eluted with 30% by volume aqueous ethanol was designated as almond seed coat extract B, and the fraction eluted with 50% by volume aqueous ethanol was designated as almond seed coat extract C.
[0041] The composition of aglycone polyphenols contained in almond seed coat extracts B and C was analyzed by liquid chromatography time-of-flight mass spectrometry. As a result, it was confirmed that almond seed coat extract B contains at least flavanone, naringenin, and epicatechin gallate, and the weight ratio of flavanone:naringenin:epicatechin gallate was 740:8.1:16. It was also confirmed that almond seed coat extract C contains at least flavanone, naringenin, eriodictyol, and liquiritigenin, and the weight ratio of flavanone:naringenin:eriodictyol:liquiritigenin was 1300:170:5500:350.
[0042] Test Example 1: GFP-DGKα Translocation Assay-1 Hamster vas deferens leiomyosarcoma (DDT1-MF2) cells were cultured in Dulbecco's modified Eagle's medium (high glucose) supplemented with 2 mM L-glutamine, 5% fetal calf serum (FBS), and 1% penicillin-streptomycin. When the cells became subconfluent, they were cultured at a concentration of 1.0 × 10 5The cells were placed in a 35 mm polylysine-coated glass bottom dish so that the cells were 1000 cells / dish, and incubated at 37°C for 24 hours. Then, a plasmid encoding DGKα fused with green fluorescent protein (GFP) (GFP-DGKα) was introduced into the cells using FuGENE HD transfection reagent (Promega). Then, a predetermined amount of each test sample was added under the conditions shown in Table 1, and the cells were incubated at 37°C for 5 minutes. Thereafter, the cells were fixed with 4% paraformaldehyde, and the localization site of GFP-DGKα in the cells was observed using a confocal fluorescence microscope, and the translocation rate of DGKα was calculated according to the following calculation formula. Then, the ratio of the translocation rate of each sample to the translocation rate of DGKα of the positive control (translocation relative ratio, %) was calculated. When DGKα is activated in the cells, DGKα is translocated from the cytoplasm to the cell membrane, so the higher the DGKα activity, the higher the translocation rate.
number
[0043] [Table 1]
[0044] Images of cells observed with a confocal fluorescence microscope are shown in Figure 1. In Figure 1, the negative control shows an image of a cell in which GFP is not localized to the cell membrane and DGKα has not been translocated from the cytoplasm to the cell membrane. In Figure 1, except for the negative control, selected images of cells in which GFP is localized to the cell membrane and DGKα has been translocated from the cytoplasm to the cell membrane are shown.
[0045] The relative translocation ratio under each condition is shown in Figure 2. As a result, it was found that almond seed coat extracts A to C containing flavanone glycosides and naringenin glycosides, flavanones, and naringenin have excellent activity of activating DGKα, and in particular, naringenin has a significantly excellent activity of activating DGKα. Although not shown in Figure 2, the relative translocation ratio in the negative control was 0%. From the above results, it was revealed that flavanones have the activity of activating DGKα.
[0046] Test Example 2: GFP-DGKα Translocation Assay-2 The translocation rate of DGKα was determined under the same conditions as in Test Example 1, except that the test sample was added under the conditions shown in Table 2.
[0047] [Table 2]
[0048] The results are shown in Figure 3. As a result, it was confirmed that almond seed coat extracts B and C, flavanone, and naringenin enhanced the effect of activating DGKα in a concentration-dependent manner.
[0049] Test Example 3: GFP-DGKα Translocation Assay-3 The translocation rate of DGKα was determined under the same conditions as in Test Example 1, except that the test sample was added under the conditions shown in Table 3. The ratios of flavanone, naringenin, and epicatechin gallate in the flavonoid mixture used in Example 6 were set to be the same as the ratios of flavanone, naringenin, and epicatechin gallate contained in the almond seed coat extract B used in Example 2.
[0050] [Table 3]
[0051] The results are shown in Figure 4. As a result, the flavonoid mixture containing flavanone, naringenin, and epicatechin gallate was also found to have an effect of activating DGKα. Furthermore, although the almond seed coat extract B used in Example 2 had the same ratio of flavanone, naringenin, and epicatechin gallate as the flavonoid mixture used in Example 6, Example 2 had a higher effect of activating DGKα than Example 6, which revealed that the almond seed coat extract has a unique composition that can improve the effect of activating DGKα.
Claims
1. A diacylglycerol kinase alpha activator comprising almond seed coat extract.
2. A diacylglycerol kinase alpha activator comprising at least one member selected from the group consisting of flavanones and their glycosides.
3. The diacylglycerol kinase alpha activator according to claim 2 , wherein the flavanone comprises a plant extract containing a flavanone.
4. The diacylglycerol kinase alpha activator according to claim 3 , wherein the plant extract is an almond seed coat extract.
5. A food or drink for activating diacylglycerol kinase α, comprising the diacylglycerol kinase α activator according to any one of claims 1 to 4.
6. The food or drink for activating diacylglycerol kinase α according to claim 5, which is used in dietary therapy for diabetic patients or patients with diabetic nephropathy.
7. A pharmaceutical for activating diacylglycerol kinase α, comprising the diacylglycerol kinase α activator according to any one of claims 1 to 4.
Citation Information
Patent Citations
Composition containing flavanone compounds
JP1999171766A
Antidiabetic agent
JP2008133192A
Antiglycation agent containing almond extract
JP2012072103A
Manufacture method for a cookie contained almond nougat
KR1020190061440A
